Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesActuate Therapeutics, Inc. Common stock

Actuate Therapeutics, Inc. Common stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.3343 USD 0.01 ( 1.67%)
Last update at 2026-11-09T15:46:00Z
VOLUME
37519
Market Cap
62.12M

Momentum Score

…

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.33
Low
0.35
High
52 Week Price Range
1.58
Low
11.99
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Actuate Therapeutics, Inc. is a Nasdaq-listed biopharmaceutical company focused on developing oncology therapies; public disclosures are limited but the company appears positioned as a clinical-stage drug developer. Long-term growth drivers may include positive clinical trial outcomes, strategic partnerships or licensing, and regulatory approvals that could support pipeline advancement and future commercialization. Investors may find interest in the potential upside tied to clinical milestones.

Key risks include high clinical and regulatory failure risk, substantial ongoing capital requirements and potential dilution, competitive pressures from larger oncology firms, and limited liquidity typical of small-cap biotech stocks.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.33
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.05
ROE
-553.75%
Net Debt
-12.75M
ROCE
-270.08%
Diluted EPS TTM
-1.06

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -22.23M -27.28M -24.74M -20.16M
Net income -22.23M -27.29M -24.74M -20.16M
Selling general administrative 12.20M 6.48M 3.27M 3.82M
Ebit - -27.30M - -
Ebitda -22.50M -25.16M - -
Depreciation and amortization - 2.14M - -
Operating income -22.50M -25.16M -24.97M -20.21M
Other operating expenses 22.49M 25.16M - -
Interest expense 0.02M 0.02M 0.04M 0.02M
Interest income 0.29M 0.22M 0.35M 0.03M
Net interest income 0.27M 0.20M 0.31M 0.01M
Income tax expense 0.00M 0.00M - -
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 22.50M 25.16M 24.97M 20.21M
Total other income expense net 0.27M -2.12M -0.08M 0.04M
Net income from continuing ops -22.23M -27.29M -24.74M -20.16M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 14.04M 9.32M 3.00M 20.48M
Other current assets 0.48M 0.57M 0.04M 0.03M
Total liab 6.11M 9.21M 102.62M 95.79M
Total stockholder equity 7.92M 0.10M -99.63M -75.31M
Other current liab 4.18M 6.88M - -
Common stock 0.00M 0.00M - -
Capital stock 0.00M 0.00M 0.00M 0.00M
Retained earnings -154.61M -132.38M -105.09M -80.35M
Cash 13.16M 8.64M 2.96M 20.45M
Total current liabilities 5.71M 8.80M 6.92M 4.34M
Net debt -12.75M -8.64M - -
Short long term debt total 0.40M 0.40M - -
Other stockholder equity 162.53M 132.48M - -
Total current assets 13.64M 9.21M 3.00M 20.48M
Accounts payable 1.52M 1.92M 3.42M 2.13M
Non currrent assets other 0.39M 0.11M - -
Non current assets total 0.39M 0.11M 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Net borrowings 0.00M 5.50M - -
Total cash from financing activities 23.72M 27.53M 4.13M 19.26M
Net income -22.23M -27.29M -24.74M -20.16M
Change in cash 4.52M 5.68M -17.49M 1.46M
Begin period cash flow 8.64M 2.96M 20.45M 18.99M
End period cash flow 13.16M 8.64M 2.96M 20.45M
Total cash from operating activities -19.21M -21.84M -21.63M -17.79M
Issuance of capital stock 23.99M 23.96M 4.13M 19.26M
Sale purchase of stock - 0.49M - -
Other cashflows from financing activities -0.30M -1.93M - -
Capital expenditures 0.00M 0.00M 0.00M 0.00M
Change in working capital -3.05M 1.10M 2.57M 1.73M
Stock based compensation 6.05M 2.00M 0.42M 0.65M
Other non cash items 0.02M 2.35M 0.04M 0.02M
Free cash flow -19.21M -21.84M -21.63M -17.79M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
ACTU
Actuate Therapeutics, Inc. Common stock		 0.01
1.67%		 0.33 - - - 7.84
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

1751 River Run, Fort Worth, TX, United States, 76107

817 887 8455

https://actuatetherapeutics.com

12

Name Title Year Born
Mr. Daniel M. Schmitt CEO, President & Director 1962
Dr. Andrew P. Mazar Ph.D. Co-Founder & COO 1962
Dr. Alan Kozikowski Ph.D. Scientific Founder and Advisor 1951
Mr. Paul J. Lytle CPA Chief Financial Officer 1968
Dr. Alan Kozikowski Ph.D. Scientific Founder and Advisor 1950

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…